Table 1.

Effect of Casodex and HDHS on cell cycle distribution in AR-dependent and AR-independent PCa cells

TreatmentsG0-G1 phaseG2-M phaseS phaseSub-G1 phase
LNCaP cells
    Control61.7 ± 1.722.0 ± 1.911.2 ± 1.20.9 ± 0.5
    Casodex (1 μmol/L)62.1 ± 3.5 *21.8 ± 2.0 *10.1 ± 1.7 *1.0 ± 0.5 *
    Casodex (10 μmol/L)61.3 ± 3.4 *22.3 ± 1.7 *10.4 ± 1.5 *1.3 ± 0.8 *
    HDHS (2.5 μmol/L)62.6 ± 2.8 *21.1 ± 2.4 *11.5 ± 2.1 *0.8 ± 0.4 *
    HDHS (5 μmol/L)66.9 ± 2.0 18.7 ± 3.5 *8.1 ± 1.8 3.9 ± 0.7
    HDHS (10 μmol/L)45.1 ± 3.1 20.2 ± 2.1 *6.8 ± 2.4 24.3 ± 3.1
22Rv1 cells
    Control52.7 ± 2.725.8 ± 2.113.4 ± 1.51.4 ± 0.6
    Casodex (1 μmol/L)53.5 ± 2.6 *25.0 ± 1.6 *13.5 ± 2.3 *1.5 ± 1.1 *
    Casodex (10 μmol/L)53.0 ± 3.2 *25.4 ± 1.0 *12.2 ± 1.8 *2.3 ± 1.8 *
    HDHS (2.5 μmol/L)54.5 ± 2.5 *24.8 ± 2.4 *11.2 ± 1.9 *2.2 ± 0.8 *
    HDHS (5 μmol/L)57.9 ± 1.9 23.7 ± 2.7 *8.0 ± 1.4 3.8 ± 0.9
    HDHS (10 μmol/L)48.4 ± 2.9 24.5 ± 2.0 *5.7 ± 2.2 14.4 ± 3.7
PC-3 cells
    Control50.0 ± 2.226.1 ± 2.119.8 ± 1.62.0 ± 0.8
    Casodex (1 μmol/L)51.1 ± 3.6 *24.4 ± 2.5 *18.5 ± 2.1 *2.3 ± 1.5 *
    Casodex (10 μmol/L)51.0 ± 2.1 *25.2 ± 2.1 *19.0 ± 1.3 *1.8 ± 1.4 *
    HDHS (2.5 μmol/L)52.7 ± 2.0 *24.9 ± 2.7 *19.2 ± 1.0 *2.3 ± 0.7 *
    HDHS (5 μmol/L)55.9 ± 2.9 19.5 ± 2.9 18.8 ± 1.1 *2.8 ± 0.9 *
    HDHS (10 μmol/L)58.2 ± 2.8 19.2 ± 3.2 18.0 ± 1.9 *2.1 ± 0.6 *
  • NOTE: The cells were treated with vehicle alone or indicated dose of treatments for 48 h, stained with propidium iodide, and analyzed by flow cytometry. Percentage of cell population in sub-G1, G0-G1, S, and G2-M phases was calculated using EXPO32 ADC analysis. Each value represents the mean ± SD from two independent experiments of four replicates. Each indicated treatment versus vehicle control was statistically compared by paired t test.

  • * P = not significant.

  • P ≤ 0.05.

  • P ≤ 0.01.